IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.822
EU - Europa 826
AS - Asia 285
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.819
UA - Ucraina 184
IT - Italia 143
SE - Svezia 135
IE - Irlanda 121
TR - Turchia 97
CN - Cina 83
DE - Germania 81
DK - Danimarca 68
FI - Finlandia 54
SG - Singapore 53
KR - Corea 36
GB - Regno Unito 28
CI - Costa d'Avorio 11
IN - India 9
FR - Francia 6
JP - Giappone 6
BE - Belgio 5
EU - Europa 4
CA - Canada 3
CZ - Repubblica Ceca 1
IR - Iran 1
Totale 2.948
Salva come PNG Salva come JPEG
Città #
Fairfield 210
Jacksonville 209
Chandler 199
Ashburn 155
Dublin 119
Wilmington 119
Des Moines 99
Woodbridge 95
Seattle 76
New York 70
Houston 69
Cambridge 50
Boardman 49
Centro 49
Lawrence 47
Princeton 47
San Mateo 43
Ann Arbor 42
Turin 28
San Diego 22
Beijing 20
Helsinki 19
Abidjan 11
London 9
Pune 9
Washington 9
Singapore 8
Kilburn 6
Los Angeles 6
Norwalk 6
Shanghai 6
Wuhan 5
Brussels 4
Izmir 4
Kagoya 3
New Bedfont 3
Redwood City 3
Toronto 3
Wuxi 3
Chicago 2
Clifton 2
Como 2
Cupra Marittima 2
Florence 2
Foshan 2
Guangzhou 2
Hounslow 2
Jiaxing 2
Montesilvano 2
Rome 2
Venice 2
Acton 1
Andover 1
Berlin 1
Chiswick 1
Chizhou 1
Dongyang 1
Hanover 1
Heze 1
Jinhua 1
Macerata 1
Marche 1
Matelica 1
Nanning 1
Naples 1
Olomouc 1
Pesaro 1
Phoenix 1
Qingdao 1
Quanzhou 1
Redmond 1
San Francisco 1
San Giuliano 1
Santa Clara 1
Somerville 1
Stamford 1
Tiantai Chengguanzhen 1
Waterloo 1
Wuhu 1
Xuzhou 1
Yiwu 1
Totale 1.988
Salva come PNG Salva come JPEG
Nome #
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 99
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 94
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 85
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 82
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 82
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 80
BRAF-mutant colorectal cancer, a different breed evolving 80
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 78
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 77
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 77
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 77
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 76
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 75
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 75
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 75
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 74
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 72
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 71
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 71
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 66
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 66
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 66
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 65
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 64
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 64
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 63
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 62
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 62
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 61
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 61
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 60
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 59
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 55
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 54
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 54
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 54
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 54
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 53
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 52
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 52
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 52
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 52
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 44
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 40
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 40
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 39
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 29
Totale 3.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.067
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020249 0 2 32 2 40 0 44 2 41 9 8 69
2020/2021735 48 85 78 7 140 40 46 65 50 78 52 46
2021/2022364 36 66 10 2 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/202578 78 0 0 0 0 0 0 0 0 0 0 0
Totale 3.043